Companies · Biotechnology

Intralink Spine, Inc.

LEXINGTON · Biotechnology

Diligence memoA one-page analyst read on Intralink Spine, Inc. — recommendation, valuation, rhythm, risks.
$1.1M
Total raised · real
2
Rounds
2.5×
Latest step-up
Top 81%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Jun 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Intralink Spine, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.09× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 10.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Intralink Spine, Inc. is one of 4293 Biotechnology companies tracked from LEXINGTON. By capital raised it ranks in the long tail (ahead of 20% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2
Investors (latest)
2016-06-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2014-06-07 Raised $325K (real) Modeled valuation $18M (est)$325K$18MPre-Seed2014Pre-Seed · 2016-06-08 Raised $800K (real) Modeled valuation $44M (est)$800K$44MPre-Seed2016+$800KCumulative $1.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$325K · 2014
Pre-Seed extension$800K · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$44.2M
Base estimate est.
$427K
Conservative case
$500.8M
Upside case
$4.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $17.9M · 2014-06-072014Pre-Seed · modeled $44.2M · 2016-06-082016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
10.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
24 mo
Avg between rounds
$561K/yr
Capital velocity
12.1 yr
On record since
2014
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.1M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.9× above median
This company$800K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$44.2M
Sector median$64.2M

Raised more than 20% of sector peers (real $). Modeled value above 43% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #17 of 152.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)Jivana Biotechnology Inc · Pre-Seed Raised $2.0M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)Gradient Pharmaceuticals, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)Intralink Spine, Inc. (this company) Raised $1.1M · modeled $44.2M (est)Intralink Spine, Inc.
CompanyStageRaised · realValue · estvs peer med.
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
Jivana Biotechnology IncPre-Seed$2.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
Gradient Pharmaceuticals, Inc.Pre-Seed$850K$46.9M2.22×
Intralink Spine, Inc. this companyPre-Seed$1.1M$44.2M2.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$325K2014-06-07$1.8M$17.9M85%
Pre-Seed$800K2016-06-08$4.4M$44.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$325K2014-06-07
    • First recorded raise — entered as Pre-Seed.
    • 3 investors on this round.
  2. Pre-Seed$800K2016-06-08
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 2 investors on this round.
Intelligence
2018 ~Q2
Modeled next raise · ~24mo cadence
$2.0M
Modeled next size est.range $1.3M$3.2M
2.5×
Last step-up
$561K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lyle Hawkins2 other2014-06
Thomas Hedman2 other2014-06
JOHN THORNE1 other2014-06
JOHN GOLLIHER2016-06
MICHAEL HAMMER2016-06
MICHAL HAMMER2014-06
Registry & provenance

Intralink Spine, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1626172
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CrossCoat Medical, LLCBiotechnologyPre-Seed$100K$5.5Mnetwork2 shared operators · same sector · same stage
Equinext, LLCBiotechnologyPre-Seed$985K$16.6Mnetwork1 shared operator · same sector · same stage
Xcellerate Biotech, Inc.BiotechnologyPre-Seed$1.1M$36.6Msame sector · same stage
Vandalia Research IncBiotechnologyPre-Seed$1.2M$41.4Msame sector · same stage
Protagenic Therapeutics Inc.BiotechnologyPre-Seed$1.0M$35.5Msame sector · same stage
Hoana Medical IncBiotechnologyPre-Seed$1.2M$35.6Msame sector · same stage
BluePrint Bio, Inc.BiotechnologyPre-Seed$1.3M$43.6Msame sector · same stage
PlenaryAI, Inc.BiotechnologyPre-Seed$1.0M$37.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Spinal Balance, Inc.BiotechnologySeries A$155.1M87%
Neuro Spine Ventures, LLCBiotechnologyPre-Seed$1.8M87%
Spineology IncBiotechnologySeries B$35.0M86%
Additive Spine, LLCBiotechnologyPre-Seed$12.7M86%
Spinal Singularity, Inc.BiotechnologySeed$88.6M86%
Aegis Spine, Inc.BiotechnologySeed$35.6M85%
IntraBio IncBiotechnologySeries C$460.0M85%
Wenzel Spine, Inc.BiotechnologySeed$10.6M84%
Frequently asked
How much funding has Intralink Spine, Inc. raised?
Intralink Spine, Inc. has raised approximately $1.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Intralink Spine, Inc.'s estimated valuation?
Provath's modeled valuation for Intralink Spine, Inc. is approximately $44.2M (modeled range $427K–$500.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Intralink Spine, Inc. at?
Intralink Spine, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Jun 08.
What does Intralink Spine, Inc. do and where is it based?
Intralink Spine, Inc. operates in the Biotechnology sector, based in LEXINGTON.
Explore related

See where Intralink Spine, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Intralink Spine, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.